

- Medical practice (*Cont.*):
 research and, 7
 trends in health care delivery, 5
- Medical records, electronic, 3
- Medical tourism, 799
- Medicare
 fee schedule, 15e-3
 health care-acquired conditions not eligible for coverage by, 912t
 hospice benefits, 70
 service covered by, 82, 83t
- Medication-overuse headache, **109**, 2593
- Medicinal leech, 274f
- Medicine, **1**
 art of, **1**
 economic issues in. *See* Economic issues
 evidence-based. *See* Evidence-based medicine
 practice of. *See* Medical practice
 science of, **1**
- Meditation, 14e-1t
- Mediterranean fever, familial. *See* Familial Mediterranean fever
- Mediterranean lymphoma, 537, 718-719
- Mediterranean spotted (boutonneuse) fever, 128t, 782, 1155t, 1157
- Medium-chain fatty acids, 1935, 1935t
- Medium-chain triglycerides, 98e-5, 1936
- MEDLINE, 25, 25t
- MEDNIK syndrome, 2519
- Medroxyprogesterone
 adverse effects of, 7e-6
 for breast cancer, 103e-15
 for contraception, 2391
 for hot flushes with androgen deprivation therapy, 7e-6
 for menorrhagia in perimenopause, 2382
 for polycystic ovarian syndrome, 337
- Medscape, 14e-4t
- Medulla, 2577f
- Medullary cystic kidney disease, 1850t, 1854
- Medullary sponge kidney, 1850t, 1855, 1866
- Medullary stroke syndrome, 2576f
- Medullary thyroid carcinoma (MTC), **2341**
 clinical features of, 269
 diagnosis of, 2341, 2341f
 familial, 2307, 2340-2341, 2342
 genetic considerations in, 2341, 2342
 in MEN 2, 2307, 2332, 2332f, 2340, 2341
 paraneoplastic syndromes in, 609t
 prevalence of, 2303t
 staging of, 2304t
 treatment of, 102e-5t, 272, 2341-2342
 tumor markers in, 473t
- Medulloblastomas, 599, 602
- Mees' lines, 2608, 2689
- Mefenamic acid, 338, 2382
- mef* gene, 807
- Mefloquine
 action of, 246e-10
 adverse effects of, 246e-5t, 246e-10, 1380t, 1381, 1383
 contraindications to, 1383
 drug interactions of, 246e-2t, 246e-5t, 246e-10, 798
 for malaria, 1378t, 1380t
 for malaria prophylaxis, 796t, 1382, 1383t
 pharmacology of, 246e-10, 1380t
 in pregnancy, 246e-5t, 246e-10, 1382
 resistance to, 1381f
- MEG (magnetoencephalography), 442e-3, 2550
- Megacolon, 273, 274, 1395. *See also* Toxic megacolon
- Megakaryocytes, 677
- Megalin, 400e-3
- Megaloblastic anemia, **641**
 autosomal recessive, 645
 biochemical basis of, 642f
 clinical features of, 642-643
 drug-induced, 647
 etiology of, 640t, 644t
 hematologic findings in, 643-644, 644f
 in orotic aciduria, 649
 peripheral blood smear in, 644f
- thiamine-responsive, 435e-1t, 649
 treatment of, 648
- Megarectum, 274
- Megestrol, 81, 310, 1795
- Meglumine antimonate, 246e-2t, 246e-7, 1390
- Meibomian gland carcinoma, 199
- Meibomitis, 199
- Meigs' disease/syndrome (lymphedema praecox), 594, 1653-1654, 2620
- Meiosis, 427-428
- MEK1* gene mutations, 507t, 509f
- MEK inhibitors, 102e-3, 102e-4f
- Melamine, 1804
- Melanin-concentrating hormone (MCH), 415e-2
- Melanocortin-2 receptor, 401e-4, 2311, 2312f
- Melanocyte(s), 386
- α -Melanocyte-stimulating hormone (MSH)
 in appetite control, 415e-3, 415e-4f, 415e-4t
 ectopic ATCH production and, 611-612
 overproduction of, 360
 sun response in skin and, 386
- Melanocytic nevus, 359
- Melanoma, 76e-6, **493**
 acral lentiginous, 76e-7f, 493f, 495, 495t
 amelanotic, 495
 AV conduction block in, 1471t
 carcinoma of unknown primary and, 120e-2t
 clinical classification of, 495, 495t
 clinical features of, 493f, 494-495
 deaths from, 467t
 desmoplastic, 495
 diagnosis of, 76e-6, 494-495
 dysplastic nevi and, 493f
 epidemiology of, 388, 493
 of eye, 40e-5f, 206, 206f
 familial, 101e-6t, 554
 genetic considerations in, 32, 101e-2t, 101e-3t, 494, 496, 496f
 incidence of, 467t, 468f
 KIRs with, 372e-15t
 lentigo maligna, 76e-7f, 493f, 495, 495t
 leukoderma in, 359
 lymphadenopathy in, 408
 metastatic, 289e-2, 360, 360t, 498-499, 553, 604t
 molecular classification of, 495-496, 496f
 nevi and, 493-494
 nodular, 76e-7f, 495, 495t
 oral, 240t
 pathogenesis of, 372e-24t, 388, 495-496, 496f
 during pregnancy, 124e-1t, 124e-4
 prevention of, 494
 prognosis of, 496, 497t
 retinopathy in, 614t, 619
 risk factors for, 493-494, 493t, 1962
 screening for, 481
 sentinel node biopsy in, 496-497
 staging of, 496, 497t
 sun/UV exposure and, 388, 476, 477t, 493, 494
 superficial spreading, 76e-7f, 339f, 495, 495t
 treatment of
 biologic therapy, 102e-17, 103e-22, 372e-30, 498-499
 chemotherapy, 499
 clinically localized disease, 496-497
 follow-up, 499-500
 metastatic disease, 497-499, 498t
 targeted chemotherapy, 102e-3, 102e-5t, 103e-17t, 103e-19, 499
- Melanopsin, 195
- Melanosis, neurocutaneous, 441e-37f
- Melanosis coli, 273
- Melanosomes, 386
- Melarsoprol, 246e-5t, 246e-10, 1398, 1398t
- Melasma, 341t, 353, 379
- MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) syndrome
 clinical features of, 85e-5, 85e-6t, 451e-3t, 462e-16, 2483
 diagnosis of, 85e-5, 441e-40f
 mitochondrial DNA mutation in, 85e-5, 85e-6t, 451e-3t, 462e-16
- Melatonin, 187, 193, 2595t
- MELD (Model for End-Stage Liver Disease) score, 1995, 1996, 2069, 2069t
- Melena, 276
- Meleney's gangrene, 1099
- Meleney's ulcer, 369
- Melioidosis, 152e-4t, 1045t, 1048
- Melkersson-Rosenthal syndrome, 2648
- Melodic intonation therapy, 178
- Melorheostosis, 426e-5
- Melphalan
 action of, 103e-8
 adverse effects of, 103e-8, 103e-9t, 621, 2025
 limb perfusion for melanoma, 498
 for multiple myeloma, 716-717
- Memantine, 176, 2601
- Membrane receptor(s), 400e-3-4, 400e-3f
- Membrane receptor families, 400e-1t
- Membrane transport, defects of, 435e-1-2, 435e-1t
- Membranoproliferative glomerulonephritis
 autoantibodies in, 372e-25t
 classification of, 1841t
 clinical features of, 1835t, 1841
 pathogenesis of, 1832, 1840-1841, 1841f
 renal biopsy in, 62e-3f, 62e-4f, 1841
 treatment of, 1841
- Membranous glomerulonephritis
 clinical features of, 1835t, 1844
 etiology of, 1843, 1843t
 pathogenesis of, 1843-1844, 1844f
 renal biopsy in, 62e-3f, 1843
 treatment of, 1844
- Memory
 assessment of, 183, 2537
 immune, 372e-2
 immunologic, 372e-16
 impairment of, rates by age group, 72t
 implicit, 182
 limbic network for, 182
 loss of. *See* Amnesia
 retentive, 183
 working, 183
- MEN1/MENIN* gene mutations
 genetic testing for, 2340
 in GI-NETs, 562-563, 562t
 in MEN syndromes, 599t, 1928, 2251, 2265-2266, 2336t, 2340, 2471, 2471f
 tumors associated with, 101e-6t
 variable expressivity of, 437
- Menaquinone, 96e-8. *See also* Vitamin K
- Menarche, 335, 524, 2379, 2379t
- Mendelian disorders, 437, 437f
 autosomal dominant, 437-438
 autosomal recessive, 438
Online Mendelian Inheritance in Man, 425, 426t
 X-linked. *See* X-linked disorders
 Y-linked, 439
- Mendelian susceptibility to mycobacterial disease (MSMD), 2106
- Mendelson's syndrome, 1098
- Ménétrier's disease, 534, **1932**, 1945
- Ménière's disease
 clinical features of, 149, 150, 219, 220
 diagnosis of, 149, 150, 223
 epidemiology of, 219
 hearing loss in, 219, 222
 nystagmus in, 210
 pathophysiology of, 150, 219
 treatment of, 150, 219
- Meningeal biopsy, 910
- Meningeal syphilis, 1136
- Meningiomas
 clinical features of, 602
 imaging in, 602, 603f, 2262
 in MEN 1, 2340
 ocular signs in, 198
 pathophysiology of, 602
 sellar, 2263
 thoracic, 2654, 2654f
 treatment of, 602